The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Venus Remedies now has 29 active product approvals in Vietnam alone
Poviztra is a second brand of Wegovy
Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
Subscribe To Our Newsletter & Stay Updated
